Erratum: An economic evaluation of aripiprazole vs olanzapine adapted to the Italian setting using outcomes of metabolic syndrome and risk for diabetes in patients with schizophrenia. Neuropsychiatr Dis Treat, 4: 967–976

ErratumColombo GL, Caruggi M, Di Matteo, et al. 2008. An economic evaluation of aripiprazole vs olanzapine adapted to the Italian setting using outcomes of metabolic syndrome and risk for diabetes in patients with schizophrenia. Neuropsychiatr Dis Treat, 4: 967–976.Page 972, Results, r...

Full description

Bibliographic Details
Main Authors: Colombo GL, Caruggi M, Di Matteo, et al
Format: Article
Language:English
Published: Dove Medical Press 2009-02-01
Series:Neuropsychiatric Disease and Treatment
Online Access:http://www.dovepress.com/erratumnbspan-economic-evaluation-of-aripiprazole-vs-olanzapine-adapte-a2836
id doaj-5ebb63c24da047e383dd2b549e53c10b
record_format Article
spelling doaj-5ebb63c24da047e383dd2b549e53c10b2020-11-24T20:49:01ZengDove Medical PressNeuropsychiatric Disease and Treatment1176-63281178-20212009-02-012008Issue 612831283Erratum: An economic evaluation of aripiprazole vs olanzapine adapted to the Italian setting using outcomes of metabolic syndrome and risk for diabetes in patients with schizophrenia. Neuropsychiatr Dis Treat, 4: 967–976Colombo GLCaruggi MDi Matteoet alErratumColombo GL, Caruggi M, Di Matteo, et al. 2008. An economic evaluation of aripiprazole vs olanzapine adapted to the Italian setting using outcomes of metabolic syndrome and risk for diabetes in patients with schizophrenia. Neuropsychiatr Dis Treat, 4: 967–976.Page 972, Results, right column, last paragraph. The second sentence should read:In the simulated cohort of 1000 patients, the values with aripiprazole for 26 weeks showed the avoidance of 34 events of diabetes over 5 years (28 in discounted scenario), resulting in total cost savings of €1,933.24 (€1,472.52 in discounted scenario).Page 973, Table 5:Under Events avoided/1000 schizophrenia patients (5 years): 18 should read 28.Under Cost/metabolic syndrome avoided (5 years): −€2,860.52 should read −€1,852.73. http://www.dovepress.com/erratumnbspan-economic-evaluation-of-aripiprazole-vs-olanzapine-adapte-a2836
collection DOAJ
language English
format Article
sources DOAJ
author Colombo GL
Caruggi M
Di Matteo
et al
spellingShingle Colombo GL
Caruggi M
Di Matteo
et al
Erratum: An economic evaluation of aripiprazole vs olanzapine adapted to the Italian setting using outcomes of metabolic syndrome and risk for diabetes in patients with schizophrenia. Neuropsychiatr Dis Treat, 4: 967–976
Neuropsychiatric Disease and Treatment
author_facet Colombo GL
Caruggi M
Di Matteo
et al
author_sort Colombo GL
title Erratum: An economic evaluation of aripiprazole vs olanzapine adapted to the Italian setting using outcomes of metabolic syndrome and risk for diabetes in patients with schizophrenia. Neuropsychiatr Dis Treat, 4: 967–976
title_short Erratum: An economic evaluation of aripiprazole vs olanzapine adapted to the Italian setting using outcomes of metabolic syndrome and risk for diabetes in patients with schizophrenia. Neuropsychiatr Dis Treat, 4: 967–976
title_full Erratum: An economic evaluation of aripiprazole vs olanzapine adapted to the Italian setting using outcomes of metabolic syndrome and risk for diabetes in patients with schizophrenia. Neuropsychiatr Dis Treat, 4: 967–976
title_fullStr Erratum: An economic evaluation of aripiprazole vs olanzapine adapted to the Italian setting using outcomes of metabolic syndrome and risk for diabetes in patients with schizophrenia. Neuropsychiatr Dis Treat, 4: 967–976
title_full_unstemmed Erratum: An economic evaluation of aripiprazole vs olanzapine adapted to the Italian setting using outcomes of metabolic syndrome and risk for diabetes in patients with schizophrenia. Neuropsychiatr Dis Treat, 4: 967–976
title_sort erratum: an economic evaluation of aripiprazole vs olanzapine adapted to the italian setting using outcomes of metabolic syndrome and risk for diabetes in patients with schizophrenia. neuropsychiatr dis treat, 4: 967–976
publisher Dove Medical Press
series Neuropsychiatric Disease and Treatment
issn 1176-6328
1178-2021
publishDate 2009-02-01
description ErratumColombo GL, Caruggi M, Di Matteo, et al. 2008. An economic evaluation of aripiprazole vs olanzapine adapted to the Italian setting using outcomes of metabolic syndrome and risk for diabetes in patients with schizophrenia. Neuropsychiatr Dis Treat, 4: 967–976.Page 972, Results, right column, last paragraph. The second sentence should read:In the simulated cohort of 1000 patients, the values with aripiprazole for 26 weeks showed the avoidance of 34 events of diabetes over 5 years (28 in discounted scenario), resulting in total cost savings of €1,933.24 (€1,472.52 in discounted scenario).Page 973, Table 5:Under Events avoided/1000 schizophrenia patients (5 years): 18 should read 28.Under Cost/metabolic syndrome avoided (5 years): −€2,860.52 should read −€1,852.73.
url http://www.dovepress.com/erratumnbspan-economic-evaluation-of-aripiprazole-vs-olanzapine-adapte-a2836
work_keys_str_mv AT colombogl erratumampnbspaneconomicevaluationofaripiprazolevsolanzapineadaptedtotheitaliansettingusingoutcomesofmetabolicsyndromeandriskfordiabetesinpatientswithschizophrenianeuropsychiatrdistreat4967ampndash976
AT caruggim erratumampnbspaneconomicevaluationofaripiprazolevsolanzapineadaptedtotheitaliansettingusingoutcomesofmetabolicsyndromeandriskfordiabetesinpatientswithschizophrenianeuropsychiatrdistreat4967ampndash976
AT dimatteo erratumampnbspaneconomicevaluationofaripiprazolevsolanzapineadaptedtotheitaliansettingusingoutcomesofmetabolicsyndromeandriskfordiabetesinpatientswithschizophrenianeuropsychiatrdistreat4967ampndash976
AT etal erratumampnbspaneconomicevaluationofaripiprazolevsolanzapineadaptedtotheitaliansettingusingoutcomesofmetabolicsyndromeandriskfordiabetesinpatientswithschizophrenianeuropsychiatrdistreat4967ampndash976
_version_ 1716807078861864960